Halozyme to Showcase Innovations at TD Cowen Healthcare Conference

Halozyme to Participate in the TD Cowen 45th Annual Healthcare Conference



Halozyme Therapeutics, Inc., listed on NASDAQ as HALO, has recently announced its upcoming participation in the prestigious TD Cowen 45th Annual Healthcare Conference. Scheduled for March 5, 2025, the presentation will be led by the company’s President and CEO, Dr. Helen Torley. This event is particularly significant as it emphasizes Halozyme's commitment to improving patient care through innovative biopharmaceutical solutions.

Conference Details


The presentation is anticipated to take place at 8:50 AM PT / 11:50 AM ET, during which Dr. Torley will also conduct investor meetings. For those unable to attend in person, a live audio webcast will be accessible via the Investor Relations section of Halozyme's official website. This will allow investors, analysts, and interested parties to engage with the company's insights and future directives. Additionally, the webcasts will be archived online for a period of 90 days post-conference, offering flexibility for audiences across different time zones.

About Halozyme Therapeutics


Established as a pioneer in biopharmaceutical development, Halozyme is recognized for its groundbreaking ENHANZE® drug delivery technology. This proprietary enzyme, rHuPH20, enables more efficient, subcutaneous delivery of medications, significantly enhancing the patient experience by reducing the treatment burden associated with traditional delivery methods. Halozyme's innovative solutions have proven beneficial for approximately one million patients, showcasing their effectiveness in more than 100 markets globally.

The company collaborates with leading pharmaceutical and biotech entities—including Roche, Takeda, and Pfizer—to utilize its ENHANZE® technology across nine commercial products. This technology enables easier administration of injected therapies, demonstrating Halozyme's pivotal role in evolving the pharmaceutical landscape to meet modern healthcare demands.

Furthermore, Halozyme also engages in the development and commercialization of drug-device combination products. By leveraging advanced auto-injector technology, these products aim to enhance patient adherence, comfort, and convenience. Among the commercial products currently available are Hylenex® and XYOSTED®, with ongoing development efforts with partners like Teva Pharmaceuticals.

Strategic Partnerships


Halozyme’s strategy to license its technology to various pharmaceutical companies reinforces its standing as a critical player in the biotechnology sector. The partnerships established not only broaden the reach of Halozyme's technology but also contribute immensely to the field of medical therapeutics. Each collaboration is intended to enhance the delivery of medications, ensuring that patients receive their treatments in the most efficient manner possible.

Looking Forward


As Halozyme prepares for the TD Cowen Conference, the focus will remain on how the company can continue to innovate and address the needs of patients and healthcare providers alike. With Dr. Torley at the helm driving strategic vision, Halozyme is poised for further advancements in its offerings and relationships within the pharmaceutical space.

In summary, Halozyme Therapeutics embodies innovation in biopharmaceuticals with a strong track record and commitment to enhancing patient care. Their participation in significant industry conferences like TD Cowen showcases their ongoing dedication to transparency and collaboration with investors while advancing healthcare solutions worldwide.

For additional details about Halozyme and its groundbreaking technologies, please visit www.halozyme.com and connect with them on social media platforms like LinkedIn and Twitter.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.